TY - JOUR
KW - Criminal justice
KW - Extended-release naltrexone
KW - Interim methadone
KW - Jail
KW - Opioid relapse prevention
AU - R. K. Chandler
AU - M. S. Finger
AU - D. Farabee
AU - R. P. Schwartz
AU - T. Condon
AU - L. J. Dunlap
AU - G. A. Zarkin
AU - K. McCollister
AU - R. D. McDonald
AU - E. Laska
AU - D. Bennett
AU - S. M. Kelly
AU - M. Hillhouse
AU - S. G. Mitchell
AU - K. E. O'Grady
AU - J. D. Lee
A1 - 
AB - BACKGROUND: Among the nearly 750,000 inmates in U.S. jails, 12% report using opioids regularly, 8% report use in the month prior to their offense, and 4% report use at the time of their offense. Although ample evidence exists that medications effectively treat Opiate Use Disorder (OUD) in the community, strong evidence is lacking in jail settings. The general lack of medications for OUD in jail settings may place persons suffering from OUD at high risk for relapse to drug use and overdose following release from jail. METHODS: The three study sites in this collaborative are pooling data for secondary analyses from three open-label randomized effectiveness trials comparing: (1) the initiation of extended-release naltrexone [XR-NTX] in Sites 1 and 2 and interim methadone in Site 3 with enhanced treatment-as usual (ETAU); (2) the additional benefit of patient navigation plus medications at Sites 2 and 3 vs. medication alone vs. ETAU. Participants are adults with OUD incarcerated in jail and transitioning to the community. RESULTS: We describe the rationale, specific aims, and designs of three separate studies harmonized to enhance their scientific yield to investigate how to best prevent jail inmates from relapsing to opioid use and associated problems as they transition back to the community. CONCLUSIONS: Conducting drug abuse research during incarceration is challenging and study designs with data harmonization across different sites can increase the potential value of research to develop effective treatments for individuals in jail with OUD.
BT - Contemporary clinical trials
C5 - Opioids & Substance Use; Healthcare Disparities; Medically Unexplained Symptoms
CY - United States
DO - 10.1016/j.cct.2016.05.003
JF - Contemporary clinical trials
N2 - BACKGROUND: Among the nearly 750,000 inmates in U.S. jails, 12% report using opioids regularly, 8% report use in the month prior to their offense, and 4% report use at the time of their offense. Although ample evidence exists that medications effectively treat Opiate Use Disorder (OUD) in the community, strong evidence is lacking in jail settings. The general lack of medications for OUD in jail settings may place persons suffering from OUD at high risk for relapse to drug use and overdose following release from jail. METHODS: The three study sites in this collaborative are pooling data for secondary analyses from three open-label randomized effectiveness trials comparing: (1) the initiation of extended-release naltrexone [XR-NTX] in Sites 1 and 2 and interim methadone in Site 3 with enhanced treatment-as usual (ETAU); (2) the additional benefit of patient navigation plus medications at Sites 2 and 3 vs. medication alone vs. ETAU. Participants are adults with OUD incarcerated in jail and transitioning to the community. RESULTS: We describe the rationale, specific aims, and designs of three separate studies harmonized to enhance their scientific yield to investigate how to best prevent jail inmates from relapsing to opioid use and associated problems as they transition back to the community. CONCLUSIONS: Conducting drug abuse research during incarceration is challenging and study designs with data harmonization across different sites can increase the potential value of research to develop effective treatments for individuals in jail with OUD.
PP - United States
PY - 2016
SN - 1559-2030; 1551-7144
SP - 166
EP - 172
EP - 
T1 - The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings
T2 - Contemporary clinical trials
TI - The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings
U1 - Opioids & Substance Use; Healthcare Disparities; Medically Unexplained Symptoms
U2 - 27180088
U3 - 10.1016/j.cct.2016.05.003
VL - 48
VO - 1559-2030; 1551-7144
Y1 - 2016
ER -